Overview

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see the affects of the study medication called mixed amphetamine salts-extended release (MAS-XR) on brain function by taking brain pictures. The researchers also want to see if MAS-XR makes your child more or less likely to develop problems like acting out (i.e. periods of irritability, agitation, aggression). MAS-XR is approved by the United States Food and Drug Administration (FDA) to treat attention deficit hyperactivity disorder (ADHD) in adults, children and adolescents.
Phase:
Phase 4
Details
Lead Sponsor:
University of Cincinnati
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Amphetamine